London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK.
Health Policy. 2012 Oct;107(2-3):146-56. doi: 10.1016/j.healthpol.2012.08.004. Epub 2012 Aug 28.
Clinical guidelines are advocated to improve the quality of care, especially for chronic diseases. However, the regulatory basis of clinical guidelines, their development, quality control, implementation and use as well as evaluation within countries across the European Union is not systematically known.
Using information collected from key informants in each country by means of a structured questionnaire, this mapping exercise illustrates the varied status of guideline production in European Union countries.
Most European Union countries have an established national, regional or local clinical guideline programme, and a substantial proportion have developed guidelines on the prevention and management of chronic diseases. Several countries have mechanisms in place to ensure the quality of scientific evidence used for the development of guidelines is high and that the process is consistent and transparent. Others are only now taking an interest in guideline development and are taking the first steps towards establishing ways of implementing them. The majority of countries have no legal basis for the development of guidelines and those that have well established systems mostly implement them on a voluntary basis. The process of guideline development varies in its degrees of decentralisation across countries with many different types of organisations taking on this responsibility. There is general acceptance of the value of the instrument developed by the AGREE collaboration for evaluating the methodological robustness of guidelines. However, the extent to which guidelines are implemented in Europe is unknown, as there is no systematic data collection and, in most countries, no structure to enable it. There are few examples of formal evaluations of the development, quality, implementation and use of guidelines.
Our findings call for renewed efforts to respond to the severe lack of standardized guideline terminology and accessibility as well as rigorous studies to evaluate the relationship between different ways to develop guidelines and their methodological quality, between their quality and the actual implementation and usage, and finally between implementation and health outcomes.
临床指南被提倡用于提高医疗质量,尤其是慢性病的医疗质量。然而,欧盟各国在临床指南的监管基础、制定、质量控制、实施和使用以及评估方面的情况并不系统。
通过对每个国家的关键信息提供者进行问卷调查,这项制图研究展示了欧盟各国制定指南的不同情况。
大多数欧盟国家都有既定的国家、地区或地方临床指南项目,其中相当一部分国家制定了慢性病预防和管理指南。一些国家建立了机制来确保用于制定指南的科学证据质量高,过程一致和透明。其他国家才刚刚对指南制定产生兴趣,正在迈出实施的第一步。大多数国家没有制定指南的法律依据,那些有完善系统的国家大多是自愿实施。指南制定的过程在各国之间存在不同程度的去中心化,许多不同类型的组织承担着这一责任。人们普遍接受 AGREE 合作制定的评估指南方法学稳健性的工具。然而,由于没有系统的数据收集,而且在大多数国家都没有能够做到这一点的结构,因此,欧洲实施指南的程度尚不清楚。很少有正式评估指南制定、质量、实施和使用的例子。
我们的研究结果呼吁做出新的努力,以应对标准化指南术语和可及性的严重缺乏,以及对不同制定指南方法与方法学质量之间的关系、其质量与实际实施和使用之间的关系、最后是实施与健康结果之间的关系进行严格研究。